search
Back to results

Preterm Premature Rupture of Fetal Membranes: Cervical Ultrasound and Biological Markers to Diagnose Prematurity (RECHOBIOL) (RECHOBIOL)

Primary Purpose

Premature Rupture of Membrane

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Vaginal secretions collection
Blood sample
Sponsored by
University Hospital, Clermont-Ferrand
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Premature Rupture of Membrane focused on measuring Preterm premature rupture of membranes, Biomarkers, Latency period, Predictive Value of Tests

Eligibility Criteria

18 Years - 60 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Parturient admitted to the Clermont-Ferrand Hospital maternity for preterm premature rupture of membranes between 24+0 and 36+4 gestation week.
  • Capacity to give informed consent.
  • Coverage by a French social security scheme.

Exclusion Criteria:

  • Refusal to participate
  • pPROM formally occurred more than 24 hours ago (free flow or positive breakage test)
  • Cervical dilatation ≥ 4 cm
  • Multiple Pregnancy
  • Known uterine malformation
  • Fetal Malformation
  • Placenta previa
  • Abundant metrorrhagia
  • Patient under guardianship or curatorship

Sites / Locations

  • CHU de Clermont-FerrandRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Eligible patients who had consented to participate

Arm Description

Eligible patients who had consented to participate to the study, namely parturient admitted to the Clermont-Ferrand Hospital maternity for preterm premature rupture of membranes between 24+0 and 36+4 gestation week with cervical dilation < 4cm and without known uterine malformation, fetal malformation, placenta previa or abundant metrorrhagia. Patients underwent vaginal swabbing and blood sample collection at the admission.

Outcomes

Primary Outcome Measures

total IGFBP1 in vaginal secretion at admission
Results of the tests detecting total IGFBP1 (positive/ negative)
native IGFBP1 in vaginal secretion at admission
Results of the tests detecting native IGFBP1 (positive/ negative)
PP14 in vaginal secretion at admission
PP14 values in vaginal secretion at admission dosed using the ELISA technique
PIBF in vaginal secretion at admission
PIBF values in vaginal secretion at admission dosed using the ELISA technique
PIBF in maternal serum at admission
PIBF values in maternal serum at admission dosed using the ELISA technique
MIF in maternal serum at admission
MIF values in maternal serum at admission dosed using the ELISA technique
Ultrasound length of cervix measured at the admission
Length of cervix was maesured by ultrasound at the admission (millmeters)

Secondary Outcome Measures

Full Information

First Posted
January 17, 2020
Last Updated
March 12, 2020
Sponsor
University Hospital, Clermont-Ferrand
Collaborators
Biosynex Company
search

1. Study Identification

Unique Protocol Identification Number
NCT04237142
Brief Title
Preterm Premature Rupture of Fetal Membranes: Cervical Ultrasound and Biological Markers to Diagnose Prematurity (RECHOBIOL)
Acronym
RECHOBIOL
Official Title
Preterm Premature Rupture of Fetal Membranes: Cervical Ultrasound and Biological Markers to Diagnose Prematurity.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
March 10, 2020 (Actual)
Primary Completion Date
March 2023 (Anticipated)
Study Completion Date
March 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Clermont-Ferrand
Collaborators
Biosynex Company

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Our main hypothesis is to consider that the detection of biomarkers on admission combined with the length of the cervix would improve the prediction of the latency period in case of preterm premature rupture of membranes (pPROM). The primary purpose of the protocol is to assess the performance of these tests to predict a latency period <48 hours in case of pPROM.
Detailed Description
Preterm premature rupture of membranes (pPROM) is defined as a spontaneous rupture before the start of labor ("premature" rupture) and before 37 weeks of gestation ("preterm"). pPROM concern 2-3% of pregnancies. It is the main cause of prematurity since it is responsible for 24 to 42% of preterm deliveries. The time between PROM and childbirth is named the latency period. Its total duration can vary from a few hours to several weeks. Childbirth occurs within 48 hours of rupture for 18 to 93% of cases, within 7 days for 56 to 96% and within 28 days for 78 to 100%. The earlier PROM occurs during pregnancy, the longer the latency period is. The factors associated with a shorter latency period are: cervical changes during admission for pPROM, a shortened cervix on ultrasound or a threat of premature delivery prior to PROM, the existence of uterine contractions, oligoamnios, and the occurrence of a materno-fetal complication of pPROM. In a pPROM situation, a prolonged latency period improves the neonatal prognosis by increasing the gestational age of birth, gives the possibility of administering the corticosteroid treatment of fetal pulmonary maturation and also allows an in utero transfer in an adapted maternity. Several studies have shown a correlation between the length of the cervix during rupture and the latency period in the context of pPROM. To date, there are no effective biomarkers used in current practice to predict this latency period. We want to assess the diagnostic performance of different vaginal (PIBF / PP14 / IGFBP1 native and total) and serum (PIBF / MIF) markers as well as the ultrasound length of the cervix to predict the duration of this latency period in order to better anticipate the risk of prematurity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature Rupture of Membrane
Keywords
Preterm premature rupture of membranes, Biomarkers, Latency period, Predictive Value of Tests

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Masking Description
Results of the biological tests are masked for the clinician and the patient and therefore do not modify the current management. Results will be given after delivery in order to not influence the current medical care of the patient.
Allocation
N/A
Enrollment
170 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Eligible patients who had consented to participate
Arm Type
Experimental
Arm Description
Eligible patients who had consented to participate to the study, namely parturient admitted to the Clermont-Ferrand Hospital maternity for preterm premature rupture of membranes between 24+0 and 36+4 gestation week with cervical dilation < 4cm and without known uterine malformation, fetal malformation, placenta previa or abundant metrorrhagia. Patients underwent vaginal swabbing and blood sample collection at the admission.
Intervention Type
Diagnostic Test
Intervention Name(s)
Vaginal secretions collection
Intervention Description
Vaginal secretions are collected under speculum with a swab (10 seconds of impregnation of the swab). The swab is immersed in a tube containing an extraction buffer for 10 seconds. The tube is mixed and sent to the laboratory for subsequent analysis of biomarkers (IGFBP1 T/N, PIBF, PP14) and storage.
Intervention Type
Diagnostic Test
Intervention Name(s)
Blood sample
Intervention Description
2 tubes of blood sample were collected and sent to the laboratory for serum storage and biomarkeurs assay (PIBF and MIF)
Primary Outcome Measure Information:
Title
total IGFBP1 in vaginal secretion at admission
Description
Results of the tests detecting total IGFBP1 (positive/ negative)
Time Frame
Day 0
Title
native IGFBP1 in vaginal secretion at admission
Description
Results of the tests detecting native IGFBP1 (positive/ negative)
Time Frame
Day 0
Title
PP14 in vaginal secretion at admission
Description
PP14 values in vaginal secretion at admission dosed using the ELISA technique
Time Frame
Day 0
Title
PIBF in vaginal secretion at admission
Description
PIBF values in vaginal secretion at admission dosed using the ELISA technique
Time Frame
Day 0
Title
PIBF in maternal serum at admission
Description
PIBF values in maternal serum at admission dosed using the ELISA technique
Time Frame
Day 0
Title
MIF in maternal serum at admission
Description
MIF values in maternal serum at admission dosed using the ELISA technique
Time Frame
Day 0
Title
Ultrasound length of cervix measured at the admission
Description
Length of cervix was maesured by ultrasound at the admission (millmeters)
Time Frame
Day 0

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Parturient admitted to the Clermont-Ferrand Hospital maternity for preterm premature rupture of membranes between 24+0 and 36+4 gestation week. Capacity to give informed consent. Coverage by a French social security scheme. Exclusion Criteria: Refusal to participate pPROM formally occurred more than 24 hours ago (free flow or positive breakage test) Cervical dilatation ≥ 4 cm Multiple Pregnancy Known uterine malformation Fetal Malformation Placenta previa Abundant metrorrhagia Patient under guardianship or curatorship
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lise LACLAUTRE
Phone
+334.73.754.963
Email
promo_interne_drci@chu-clermontferrand.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Denis Gallot
Organizational Affiliation
University Hospital, Clermont-Ferrand
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU de Clermont-Ferrand
City
Clermont-Ferrand
ZIP/Postal Code
63000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lise Laclautre
Phone
+33473754963
Email
promo_interne_drci@chu-clermontferrand.fr
First Name & Middle Initial & Last Name & Degree
Denis Gallot

12. IPD Sharing Statement

Learn more about this trial

Preterm Premature Rupture of Fetal Membranes: Cervical Ultrasound and Biological Markers to Diagnose Prematurity (RECHOBIOL)

We'll reach out to this number within 24 hrs